52817-12-6

Basic information

• Product Name: 6-BROMO-3-FORMYLCHROMONE
• Synonyms: 6-BROMO-3-FORMYLCHROMONE;6-BROMO-4-OXO-4H-1-BENZOPYRAN-3-CARBOXALDEHYDE;6-BROMO-4-OXO-4H-CHROMENE-3-CARBALDEHYDE;6-BROMO-3-FORMYLCHROMONE 99%;6-Bromo-4-oxo-4H-1-benzopyran-3-carboxaldehyde 6-Bromochromone-3-carboxaldehyde;4H-1-Benzopyran-3-carboxaldehyde, 6-bromo-4-oxo-;6-bromo-4-keto-chromene-3-carbaldehyde;6-bromo-4-oxo-3-chromenecarboxaldehyde
• CAS NO: 52817-12-6
• Molecular Formula: C₁₀H₅BrO₃
• Molecular Weight: 253.05
• EINECS: 123-562-6
• Product Categories: Chromones
• Mol File: 52817-12-6.mol
• Article Data: 25

Chemical Properties

• Melting Point: 190-193 °C(lit.)
• Boiling Point: 365.7 °C at 760 mmHg
• Flash Point: 175 °C
• Appearance: /
• Density: 1.835g/cm³
• Refractive Index: 1.713
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 6-BROMO-3-FORMYLCHROMONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3-FORMYLCHROMONE(52817-12-6)
• EPA Substance Registry System: 6-BROMO-3-FORMYLCHROMONE(52817-12-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 52817-12-6(Hazardous Substances Data)

Usage

Uses

6-Bromo-3-formylchromone is the suitable reagent used in a study to investigate the multidrug resistance reversal by some 3- formylchromones in human colon cancer and mouse lymphoma cells transfected with the human MDR1 gene. It may be used in the preparation of chromone containing sulfonamides.

General Description

6-Bromo-3-formylchromone (6-Bromo-4-oxo-4H-1-benzopyran-3-carboxaldehyde) is a 3-formylchromone derivative. In vivo cytotoxic activity of 6-bromo-3-formylchromone against normal and tumor cells has been tested.

InChI:InChI=1/C10H5BrO3/c11-7-1-2-8-9(3-7)14-5-6(4-12)10(8)13/h1-5H

Upstream product

• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 68-12-2 N,N-dimethyl-formamide 
• 106-41-2 4-bromo-phenol 
• 1927-95-3 4-bromophenyl acetate 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 68827-57-6 6-bromo-3-(4,5-diphenyl-1H-imidazol-2-yl)-chromen-4-one 
• 95664-49-6 (2-Amino-pyrimidin-5-yl)-(5-bromo-2-hydroxy-phenyl)-methanone 
• 51085-91-7 6-bromo-4-oxo-4H-chromene-3-carboxylic acid 
• 68101-18-8 N′-((6-bromo-4-oxo-4H-chromen-3-yl)methylene)benzohydrazide 
• 916515-46-3 (5-bromo-2-hydroxy-phenyl)-[1-(2-bromo-phenyl)-1H-pyrazol-4-yl]-methanone 
• 52817-13-7 6-bromochromone-3-carbonitrile 
• 939437-68-0 (5-bromo-2-hydroxyphenyl)-[1-(3,5-dichloropyridin-2-yl)-1H-pyrazol-4-yl]methanone 
• 1005791-79-6 (5-bromo-2-hydroxyphenyl)-[4-hydroxy-3-(2-methoxybenzoyl)phenyl]methanone 
• 1005791-82-1 (5-bromo-2-hydroxyphenyl)-[3-(4-fluorobenzoyl)-4-hydroxyphenyl]methanone 

Relevant articles and documents

Synthesis of Chromeno[2,3-d]pyrimidin-5-one Derivatives from 1,3,5-Triazinanes via Two Different Reaction Pathways

1,3,5-Triazinanes, as a kind of versatile building block, are applied in the synthesis of chromeno[2,3-d]pyrimidin-5-one derivatives via two different reaction modes, which perfectly exhibits the powerful function of 1,3,5-triazinane as a three-atom synth

NHC-Catalyzed Cascade Reaction between β-Methyl Enals and Dienones for Quick Construction of Complex Multicyclic Lactones

A NHC-promoted cascade reaction between β-methyl enal and dienone is developed for quick access to multicyclic lactone molecules bearing quaternary chiral carbon centers. Our study constitutes the first 1,6-addition of the acylazolium vinyl enolate γ-carbon via NHC catalysis and provides rapid access to complex lactone molecules that are otherwise difficult to prepare. The structurally sophisticated lactone products bearing up to four fused ring structures are afforded in up to quantitative yields with good to excellent enantioselectivities.

Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease

A series of chromone and donepezil hybrids were designed, synthesized, and evaluated as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential therapy of Alzheimer's disease (AD). In vitro studies showed that the great majority of these compounds exhibited potent inhibitory activity toward BuChE and AChE and clearly selective inhibition for hMAO-B. In particular, compound 5c presented the most balanced potential for ChE inhibition (BuChE: IC50 = 5.24 μM; AChE: IC50 = 0.37 μM) and hMAO-B selectivity (IC50 = 0.272 μM, SI = 247). Molecular modeling and kinetic studies suggested that 5c was a mixed-type inhibitor, binding simultaneously to peripheral and active sites of AChE. It was also a competitive inhibitor, which occupied the substrate and entrance cavities of MAO-B. Moreover, compound 5c could penetrate the blood-brain barrier (BBB) and showed low toxicity to rat pheochromocytoma (PC12) cells. Altogether, these results indicated that compound 5c might be a hopeful multitarget drug candidate with possible impact on Alzheimer's disease therapy.